Rohan Katipally / Astro Foundation
Dr. Rohan Katipally, an Indian-origin radiation oncologist and researcher at the University of Chicago Medicine, has been named a recipient of the prestigious 2026 Innovation Award by Speed of Light – The ASTRO Foundation.
The grant and recognition are awarded to top researchers pioneering groundbreaking approaches in oncology, specifically focusing on how to optimally combine radiation therapy and immunotherapy to improve outcomes for cancer patients.
Dr. Katipally, assistant professor of radiation and cellular oncology at the University of Chicago Medicine, has been awarded for his research on radiotherapy and immunotherapy in HPV-negative head and neck cancer.
He shared the award with Sabrina Campelo, Ph.D., The University of Texas MD Anderson Cancer Center, and Yvonne Mowery, M.D., Ph.D., University of Pittsburgh.
“These awards will support research to better understand how to optimally combine radiation therapy and immunotherapy,” The ASTRO Foundation said on X while announcing the award.
The awardees will be formally honored and recognized during the official Awards Ceremony at the upcoming American Society for Radiation Oncology Annual Meeting.
The American Society for Radiation Oncology (ASTRO) and Speed of Light – The ASTRO Foundation have announced $2.4 million in new research grants for 14 scientists working to advance patient care in radiation medicine.
Congratulations to the 2026 Innovation Award Winners:
— Speed of Light - The ASTRO Foundation (@SpeedofLightFdn) August 12, 2026
- Sabrina Campelo, PhD
- Rohan Katipally, MD
- Yvonne Mowery, MD, PhD
These awards will support research to better understand how to optimally combine radiation therapy and immunotherapy.
We look forward to recognizing them… pic.twitter.com/dRxQeZ06Mu
The 2026 awards are the first annual grants announced since ASTRO relaunched its foundation as Speed of Light earlier this year, with a renewed focus on accelerating research and strengthening the radiation oncology workforce.
Also Read: Indian-origin researcher awarded for prostate cancer study
“ASTRO and its nonprofit Foundation are committed to fostering progress in radiation medicine by investing in innovative research and the people driving it,” said Vivek S. Kavadi, CEO of ASTRO.
“These awards come at a pivotal moment for the field, as scientific advances in radiation oncology are expanding even as research funding becomes more constrained. By supporting promising investigators, we can speed the translation of new discoveries into better treatments and cures for patients.”
Since 2013, ASTRO and its Foundation, in collaboration with research partners, have awarded $15.8 million to more than 150 research teams. These investigators have subsequently attracted more than $90 million in follow-on funding, extending the impact of the combined investment.
Discover more at New India Abroad.
ADVERTISEMENT
ADVERTISEMENT
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login